Skip to content
Search

Latest Stories

The 'most notable' opportunity for pharmacy owners to capitalise upon in 2024 revealed

The 'most notable' opportunity for pharmacy owners to capitalise upon in 2024 revealed

Overall, pharmacy goodwill prices are anticipated to remain consistent in the coming months 

Pharmacy sales specialist, Hutchings Consultants has revealed its market predictions for the next 12 months in a new report.


The broker is anticipating that both independent group operators and corporate owners will continue to reassess their existing portfolios in 2024, making strategic disposals of varying sizes.

“This is likely to result in transaction volumes remaining high for the foreseeable future,” stated the report authored by Paul Steet, Associate Director, Hutchings Consultants.

Community Pharmacy Contractual Framework negotiations will be the most notable opportunity for the sector to capitalise upon this year, the broker said, adding that it’s “a belated opportunity for the sector to secure a vital uplift to the contract’s fixed global sum.”

The launch of Pharmacy First Scheme in England is seen as a positive development, as Paul said it offers “a much-needed financial boost” to the sector.

He said that the new scheme and the recent announcement of a 5% funding increase in Wales are “already bringing a renewed degree of confidence from buyers as we move into 2024.”

Additionally, the broker has anticipated some reduction in interest rates by the Bank of England in coming months, relieving the financial pressure felt by existing operators to certain extent and assisting buyers with affordability.

Overall, pharmacy goodwill prices are expected to remain consistent during the year unless “the supply of pharmacies on the market falls further or a more significant uplift in community pharmacy funding is secured.”

Hutchings encourages pharmacy owners to focus on their drug buying and profit margin through 2024 as “this is such a key factor for pharmacy goodwill values.”

A look back at 2023

Hallo Healthcare Group’s decision to divest their portfolio of over 1,054 Lloyds Pharmacies resulted in an unprecedented increase in the number of business opportunities on the UK pharmacy market in initial six months of 2023.

The divestment created a “fever-pitch level” of demand from potential buyers both within the market and outside, according to the Hutchings report.

In Scotland alone, Lloyd’s disposals resulted in a massive 533 per cent increase in completed deals at Hutchings.

Although on a significantly smaller scale, Boots and Well also opted to divest some branches, with the former announcing its plan to axe 300 branches around the UK.

Existing pharmacy owners with single branches completed most corporate acquisitions last year, while first-time buyers acquired the majority of the independent sales, according to the broker.

Hutchings saw a significant increase in the number of enquiries and registrations from both new and existing buyers for pharmacy triggered by large-scale corporate disposals in 2023.

In 2023, the number of new buyer registrations increased over 90 per cent, compared to the previous year.

At 77 per cent, first-time buyers accounted for the majority of the new registrations, followed by existing owners at 15 per cent.

Almost all sales the broker transacted last year involved the buyer obtaining a bank loan.

More For You

Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Asda pharmacy launches UK’s first adult earache service

Asda makes ear health more accessible for everyone

gettyimages

Asda pharmacy launches £25 adult earache service

British supermarket chain Asda has launched the “UK’s first” adult earache service, aiming to reduce the burden on NHS services by eliminating the need for a GP appointment.

Priced at £25, the service allows patients aged 18 and over to book same-day appointments with qualified Asda pharmacists at any of its 226 pharmacies in England.

Keep ReadingShow less
Dr Penelope Dash new chair of NHS England

Dr Penny Dash is currently the chair of the NHS North West London Integrated Care Board

parliamentlive

Dr Penelope Dash appointed as new chair of NHS England

Dr Penny Dash has been appointed as the next chair of NHS England following an open public appointment process.

She will succeed Richard Meddings, who is set to step down next month, and her four-year term begins on April 1, 2025.

Keep ReadingShow less